Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EVGN.TA
- Price
- 2.92
- Stock movement down
- -0.08 (-2.67%)
- Company name
- Evogene
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 25.46M
- Ent value
- 28.67M
- Price/Sales
- 4.85
- Price/Book
- 1.48
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.18%
- 1 year return (CAGR)
- -47.06%
- 3 year return (CAGR)
- -52.47%
- 5 year return (CAGR)
- -54.49%
- 10 year return (CAGR)
- -36.04%
Last updated: 2026-03-09
DIVIDENDS
EVGN.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.85 |
| Price to Book | 1.48 |
| EV to Sales | 5.46 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.72M |
| EPS (TTM) | -0.32 |
| FCF per share (TTM) | -1.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.25M |
| Gross profit (TTM) | 2.59M |
| Operating income (TTM) | -14.49M |
| Net income (TTM) | -2.75M |
| EPS (TTM) | -0.32 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 49.30% |
| Operating margin (TTM) | -275.91% |
| Profit margin (TTM) | -52.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.63M |
| Net receivables | 1.99M |
| Total current assets | 20.06M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.36M |
| Total assets | 26.09M |
| Accounts payable | 457.00K |
| Short/Current long term debt | 2.52M |
| Total current liabilities | 4.08M |
| Total liabilities | 8.83M |
| Shareholder's equity | 17.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.02M |
| Capital expenditures (TTM) | 452.00K |
| Free cash flow (TTM) | -16.48M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -15.93% |
| Return on Assets | -10.53% |
| Return on Invested Capital | -15.93% |
| Cash Return on Invested Capital | -95.50% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.08 |
| Daily high | 3.08 |
| Daily low | 2.92 |
| Daily Volume | 55K |
| All-time high | 128920.00 |
| 1y analyst estimate | 5.50 |
| Beta | 1.08 |
| EPS (TTM) | -0.32 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| EVGN.TA | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -65.11% | -10.84% |
| Avg time to new high | 64 days | 12 days |
| Max time to new high | 3015 days | 1805 days |
COMPANY DETAILS
Marketcap
25.46M
Marketcap category
Small-cap
Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop Novel Therapies forfor hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Employees
117
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries...
March 9, 2026
Moby summary of Evogene Ltd.'s Q4 2025 earnings call
March 6, 2026
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $5.3 million in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had a loss of 61 cents. Th...
March 5, 2026
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries...
March 5, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries to...
February 25, 2026
Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries,...
February 19, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today...
February 17, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Syst...
February 11, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and...
February 10, 2026
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for the pharmaceutical and agricultural industries, today announced an expanded p...
February 10, 2026
Next page